Heather Moore
Articles
-
Jul 25, 2024 |
cancernetwork.com | Heather Moore |Avirup Guha |Irene Arias |Stella Stergiopoulos |Benjamin Li |Michael G. Fradley | +3 more
BackgroundThe prevalence of preexisting cardiovascular (CV) comorbidities at diagnosis of hormone receptor-positive (HR+)/HER2-negative (HER2–) metastatic breast cancer (mBC) has not been well established. We aimed to describe the prevalence of preexisting CV comorbidities in patients with newly diagnosed HR+/HER2– mBC and to describe the first documented cancer treatment and concurrent medications with risk of QT interval (QTc) prolongation for patients with or without CV comorbidities.
-
May 28, 2024 |
pharmacytimes.com | Ryan Haumschild |Heather Moore |Britny R. Brown |Frank Scimeca
Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast CancerHeather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.
-
Feb 23, 2024 |
cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent
2 Commerce Drive Cranbury, NJ 08512
-
Feb 16, 2024 |
cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent
2 Commerce Drive Cranbury, NJ 08512
-
Feb 16, 2024 |
cancernetwork.com | Carey Anders |Heather Moore |Rani Bansal |Susan Dent
2 Commerce Drive Cranbury, NJ 08512
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →